Press Release: Sanofi completes acquisition of Inhibrx, Inc. [Yahoo! Finance]
Inhibrx Biosciences, Inc. (INBX)
Company Research
Source: Yahoo! Finance
Inhibrx, Inc . (“Inhibrx”). The acquisition adds SAR447537 (formerly INBRX-101) to Sanofi's rare disease pipeline, underscoring the company's commitment to pursuing differentiated and potential best-in-class medicines that build upon our existing strengths and capabilities. SAR447537 is a human recombinant protein that holds the promise of allowing alpha-1 antitrypsin deficiency (AATD) patients to achieve normalization of serum AAT levels with less frequent (monthly vs. weekly) dosing. AATD is an inherited rare disease characterized by low levels of AAT protein, predominantly affecting the lung with progressive deterioration of the tissue. SAR447537 may help to reduce inflammation and prevent further deterioration of lung function in affected individuals. The former holders of shares of Inhibrx common stock voted to approve the acquisition at a special meeting of stockholders on May 24, 2024. Upon the closing of the acquisition, former shareholders of Inhibrx became entitled to re
Show less
Read more
Impact Snapshot
Event Time:
INBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INBX alerts
High impacting Inhibrx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
INBX
News
- Inhibrx gets stockholders approval to sell INBRX-101 to Sanofi [Seeking Alpha]Seeking Alpha
- Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to SanofiPR Newswire
- Single Domain Antibody Platforms MarketResearch 2024-2031: Strategic Collaborations Driving Expansion, Focus on Pioneering Cancer Treatments, US Leads Innovations [Yahoo! Finance]Yahoo! Finance
- Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-OffPR Newswire
- INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXBusiness Wire
INBX
Earnings
- 2/28/24 - Miss
INBX
Sec Filings
- 6/10/24 - Form 15-12G
- 6/3/24 - Form SC
- 6/3/24 - Form 4
- INBX's page on the SEC website